Announcements Trials

Browse Landscape

Phase

Phase NA 4 Phase 2 3 Phase 3 2 Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 39 Glioblastoma 37 Glioma 33 Prostatic Neoplasms 32 Neoplasms 28 Multiple Myeloma 26 Pancreatic Neoplasms 25 Brain Neoplasms 23 Colorectal Neoplasms 19 Recurrence 18 Squamous Cell Carcinoma of Head and Neck 16 Melanoma 15 Lung Neoplasms 15 Neoplasm Metastasis 14 Lymphoma, B-Cell 13 Lymphoma 13 Carcinoma, Non-Small-Cell Lung 13 Triple Negative Breast Neoplasms 12 Sarcoma 12 Leukemia, Myeloid, Acute 12 Hematologic Neoplasms 12 Head and Neck Neoplasms 12 Advanced Solid Tumors 10 Stomach Neoplasms 9 Ovarian Neoplasms 9 Skin Neoplasms 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Neuroblastoma 8 Lymphoma, Non-Hodgkin 8 Colonic Neoplasms 8

Interventions

tislelizumab 1 molgramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Pseudomyxoma Peritonei × 1 year × Clear all

NCT07341360 2026-01-14

Pseudovax

Oslo University Hospital

Phase EARLY_PHASE1 Recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡